Skip to content

ACTU - ACTUATE THERAPEUTICS, INC. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

Actuate Therapeutics, Inc. Common stock

ACTU · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

ACTUActuate Therapeutics, Inc. Common stock

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $9.22
52-wk low: $0.90
Prev close: $4.96
Mkt cap: $25.5M
P/B: 25.5x
Profit margin: +0.0%

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$585K

AQ
AQR
Q2 2026 13F
$195K
position
MI
Millennium
Israel Englander · Q2 2026 13F

Earnings

Reported Aug 13, 2026

Earnings came in 4.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $25M

Valuation

P/B25.49

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: ACTU
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $25.46M

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Op margin

+0.0%

ROE

-554.0%

$148K

position

QR

Qube Research

Q2 2026 13F

$23K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for ACTU

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.20+4.8%

-$0.21 expected

Next report

What the street expects next

EPS expected

-$0.19

-$0.21 to -$0.15

Revenue expected

$0.00

4 analysts

Last 30 days

1up2down

Analysts cutting estimates

Estimate drift

0.01

Change in 30 days

-554.0%

ROA-203.8%

Growth